Literature DB >> 12937123

Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis.

Karin Hartmann1, Metin Artuc, Stephan E Baldus, Thomas K Zirbes, Barbara Hermes, Juergen Thiele, Yoseph A Mekori, Beate M Henz.   

Abstract

Mastocytosis is a rare disease characterized by accumulation of mast cells in tissues. To investigate whether an altered regulation of mast cell apoptosis might be involved in the pathogenesis of mastocytosis, expression of the apoptosis-preventing molecules bcl-2 and bcl-xL was studied by immunohistochemistry in skin and bone marrow lesions of mastocytosis patients. In addition, reverse transcription-polymerase chain reaction was used to investigate levels of bcl-2 and bcl-xL mRNA in cutaneous mastocytosis lesions. Since activating mutations of c-kit are known to be associated with some forms of mastocytosis, human mast cell cultures were also stimulated via c-kit and the expression of bcl-2 and bcl-xL was assessed by immunoblotting. In patients with mastocytosis, the expression of bcl-2 protein but not bcl-xL in cutaneous mast cells was significantly enhanced, compared to healthy controls. Evaluating different subgroups of adult and pediatric mastocytosis patients, all groups were found to express significantly increased levels of bcl-2 protein, and none of the patient groups was found to overexpress bcl-xL, with the exception of solitary mastocytomas that showed a tendency for up-regulated bcl-xL protein. Furthermore, the expression of bcl-2 mRNA was significantly enhanced in cutaneous lesions of adult and pediatric patients, while bcl-xL mRNA levels were only slightly increased in pediatric, but not in adult patients with mastocytosis. In contrast to the skin lesions, bone marrow infiltrates of patients with systemic mastocytosis showed only low or absent immunoreactivity for bcl-2, but marked expression of bcl-xL. In vitro, stimulation of two different mast cell culture systems by activation of c-kit resulted in up-regulation of bcl-2 and also in an increase of bcl-xL, although less pronounced. Thus, overexpression of bcl-2 and bcl-xL leading to prolonged survival of mast cells may contribute to the pathogenesis of mastocytosis. Our findings may help to develop new strategies for the treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12937123      PMCID: PMC1868267          DOI: 10.1016/S0002-9440(10)63442-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  Classification of cutaneous mastocytosis: a modified consensus proposal.

Authors:  Karin Hartmann; Beate M Henz
Journal:  Leuk Res       Date:  2002-05       Impact factor: 3.156

2.  Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival.

Authors:  J Kalesnikoff; M Huber; V Lam; J E Damen; J Zhang; R P Siraganian; G Krystal
Journal:  Immunity       Date:  2001-06       Impact factor: 31.745

Review 3.  Dysregulation of apoptosis genes in hematopoietic malignancies.

Authors:  Shinichi Kitada; Irene M Pedersen; Aaron D Schimmer; John C Reed
Journal:  Oncogene       Date:  2002-05-13       Impact factor: 9.867

4.  Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.

Authors:  S Kitada; J Andersen; S Akar; J M Zapata; S Takayama; S Krajewski; H G Wang; X Zhang; F Bullrich; C M Croce; K Rai; J Hines; J C Reed
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

5.  Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL.

Authors:  Y A Mekori; A M Gilfillan; C Akin; K Hartmann; D D Metcalfe
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

Review 6.  Mastocytosis: molecular mechanisms and clinical disease heterogeneity.

Authors:  D D Metcalfe; C Akin
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

Review 7.  Antisense therapeutics: lessons from early clinical trials.

Authors:  K T Flaherty; J P Stevenson; P J O'Dwyer
Journal:  Curr Opin Oncol       Date:  2001-11       Impact factor: 3.645

8.  Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).

Authors:  J H Jordan; S Walchshofer; W Jurecka; I Mosberger; W R Sperr; K Wolff; A Chott; H J Bühring; K Lechner; H P Horny; P Valent
Journal:  Hum Pathol       Date:  2001-05       Impact factor: 3.466

9.  Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.

Authors:  B Jahrsdörfer; R Jox; L Mühlenhoff; K Tschoep; A Krug; S Rothenfusser; G Meinhardt; B Emmerich; S Endres; G Hartmann
Journal:  J Leukoc Biol       Date:  2002-07       Impact factor: 4.962

10.  Essential role of the prosurvival bcl-2 homologue A1 in mast cell survival after allergic activation.

Authors:  Z Xiang; A A Ahmed; C Möller; K Nakayama; S Hatakeyama; G Nilsson
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

View more
  5 in total

1.  Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1.

Authors:  Chengguo Xing; Liangyou Wang; XiaoHu Tang; Yuk Y Sham
Journal:  Bioorg Med Chem       Date:  2006-12-14       Impact factor: 3.641

2.  IL-33/ST2 axis promotes mast cell survival via BCLXL.

Authors:  Jun-Xia Wang; Shinjiro Kaieda; Sarah Ameri; Nadia Fishgal; Daniel Dwyer; Anthony Dellinger; Christopher L Kepley; Michael F Gurish; Peter A Nigrovic
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

Review 3.  Mast Cells in the Skin: Defenders of Integrity or Offenders in Inflammation?

Authors:  Martin Voss; Johanna Kotrba; Evelyn Gaffal; Konstantinos Katsoulis-Dimitriou; Anne Dudeck
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

Review 4.  Preclinical human models and emerging therapeutics for advanced systemic mastocytosis.

Authors:  Michel Arock; Ghaith Wedeh; Gregor Hoermann; Siham Bibi; Cem Akin; Barbara Peter; Karoline V Gleixner; Karin Hartmann; Joseph H Butterfield; Dean D Metcalfe; Peter Valent
Journal:  Haematologica       Date:  2018-07-05       Impact factor: 9.941

Review 5.  Controlling Mast Cell Activation and Homeostasis: Work Influenced by Bill Paul That Continues Today.

Authors:  Heather L Caslin; Kasalina N Kiwanuka; Tamara T Haque; Marcela T Taruselli; H Patrick MacKnight; Anuya Paranjape; John J Ryan
Journal:  Front Immunol       Date:  2018-04-26       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.